Search Results

search
plus_logo.png
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
February 20, 2025 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
plus_logo.png
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
February 18, 2025 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
MonoparTherapeuticsInc..png
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
December 05, 2024 16:21 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet...
plus_logo.png
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
December 03, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
plus_logo.png
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
November 25, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
plus_logo.png
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
November 22, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay
plus_logo.png
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
November 21, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
plus_logo.png
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024 16:15 ET | Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
MonoparTherapeuticsInc..png
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
November 08, 2024 08:00 ET | Monopar Therapeutics Inc.
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid...
plus_logo.png
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
November 06, 2024 07:30 ET | Plus Therapeutics Inc.; Spectron RX
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership